logo

For the Inventor, By the Inventor

Houston, TX, United States of America

Kenji Nishioka

This inventor holds 8 USPTO granted patents. Top assignees: The University of Texas System, Other. Active years: 1983-2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenji Nishioka. Retrieved from https://idiyas.com/inventor/kenji-nishioka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 8

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 5

Forward Citations = 103(Granted Patents)


Location History:

  • Redwood City, CA (US) (1983)
  • Houston, TX (US) (1989 - 2001)

Company Filing History:

goldMedal6 out of 5,644 
 
The University of Texas System
 patents
silverMedal2 out of 834,601 
Other
 patents

Years Active: 1983-2001

Loading Chart...
8 patents (USPTO):Explore Patents
1. 6177405 - Cyclic analogs of tuftsin (2001-01-23),
2. 6166079 - DFMO for the treatment or prevention of cervical intraepithelial (2000-12-26),
3. 5189025 - Methods for the treatment of malignant disease in patients using (1993-02-23),
4. 5162373 - Methods and improved formulations for the determination and treatment of (1992-11-10),
5. 5028593 - Tuftsin analogs (1991-07-02),
6. 4988724 - Methods and improved formulations for the determination and treatment of (1991-01-29),
7. 4859452 - Methods for the reduction of difluoromethylornithine associated toxicity (1989-08-22),
8. 4386157 - Method for detecting coliform organisms (1983-05-31),

Title: Kenji Nishioka: Innovator in Medical Treatments

Introduction

Kenji Nishioka is a prominent inventor based in Houston, TX, known for his significant contributions to medical science. With a total of 8 patents to his name, he has made strides in developing innovative treatments for various health conditions.

Latest Patents

Among his latest patents are cyclic analogs of tuftsin, specifically the useful cyclic peptides cyclo[Thr-Lys-Pro-Arg-Gly] and cyclo[Thr-Lys-Pro-Arg-Asp]. These peptides have potential applications in enhancing immune responses. Additionally, he has developed methods for the treatment or prevention of cervical intraepithelial neoplasia, focusing on the use of DFMO. His work provides methods for treating, preventing, and controlling the growth of cervical cancer, particularly in patients with cervical intraepithelial neoplasia, using pharmaceutically acceptable preparations of DFMO.

Career Highlights

Kenji Nishioka has had a notable career, working with the University of Texas System, where he has contributed to various research initiatives. His innovative approaches have garnered attention in the medical community, particularly in the field of cancer treatment.

Collaborations

Throughout his career, Nishioka has collaborated with esteemed colleagues, including Jaffer Ajani and Bruce Grossie, Jr. These partnerships have furthered his research and development efforts in medical innovations.

Conclusion

Kenji Nishioka's work exemplifies the impact of innovation in medicine, particularly in the fight against cancer. His patents and collaborations highlight his commitment to advancing healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…